Evidence map›Paper›PMID 29495389›Full record

ArticleInternational journal of molecular sciences2018

The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.

Marta Kotlarek, Anna Kubiak, Małgorzata Czetwertyńska, Michał Świerniak, Wojciech Gierlikowski, Monika Kolanowska, Elwira Bakuła-Zalewska, Sissy M Jhiang, Krystian Jażdżewski, Anna Wójcicka

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma.International journal of molecular sciences · 2021
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Marta KotlarekGenomic Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. mkotlarek@wum.edu.pl.ORCID 0000-0002-6703-1253
Anna KubiakGenomic Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. a.kubiak@cent.uw.edu.pl.
Małgorzata CzetwertyńskaDepartment of Nuclear Medicine & Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland. malgorzata.czetwertynska@coi.pl.
Michał ŚwierniakGenomic Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. m.swierniak@cent.uw.edu.pl.
Wojciech GierlikowskiGenomic Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. wgierlikowski@wum.edu.pl.
Monika KolanowskaGenomic Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. m.kolanowska@cent.uw.edu.pl.
Elwira Bakuła-ZalewskaDepartment of Pathology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland. elwirabz@onet.eu.
Sissy M JhiangDepartment of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210, USA. jhiang.1@osu.edu.
Krystian JażdżewskiGenomic Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. k.jazdzewski@cent.uw.edu.pl.
Anna WójcickaGenomic Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. awojcicka@wum.edu.pl.
Medical University of Warsaw · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Selective Modulation of Thyroidal RadioiodineP01CA124570 · NCI · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2008 to 2017
$23.4M
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPOREP50CA168505 · NCI · OHIO STATE UNIVERSITY · PI DE LA CHAPELLE, ALBERT · 2013 to 2017
$10.9M
NCI NIH HHS P01 CA124570NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA168505
6 · The paper itself

Abstract

Aberrant expression of the sodium-iodide symporter (NIS) and the resistance to post-operative radioactive iodide treatment is a crucial cause of higher mortality of some thyroid cancer patients. In this study, we analyzed the impact of miR-146a on the expression and function of NIS and on the overall survival of thyroid cancer patients. The study included 2441 patients (2163 women; 278 men); including 359 cases with follicular variant of papillary thyroid carcinoma (fvPTC). miR:

Indexed as

AllelesGenetic Variation3' Untranslated RegionsAdultAgedCarcinoma, PapillaryFemaleGene Expression Regulation, NeoplasticGenotypeHumansKaplan-Meier EstimateMaleMicroRNAsMiddle AgedMutationNeoplasm Grading3' Untranslated RegionsMicroRNAsMIRN146 microRNA, humanSodium-Iodide SymportersSymportersmicroRNAmiRNA-146apapillary thyroid carcinoma (PTC)rs2910164thyroid carcinoma

Identifiers

PMID29495389
PMCPMC5877516
OpenAlexW2791776694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.